{"title": "Dosage and Administration for RotaTeq\u00ae (Rotavirus Vaccine, Live, Oral, Pentavalent)", "author": null, "url": "https://www.merckvaccines.com/rotateq/dosage-and-administration/", "hostname": "merckvaccines.com", "description": "View the dosing schedule for RotaTeq\u00ae (Rotavirus Vaccine, Live, Oral, Pentavalent) and watch a video on the administration of RotaTeq.", "sitename": "MerckVaccines.com", "date": "2023-05-22", "cleaned_text": "A DOSING SCHEDULE THAT IS FLEXIBLE FOR YOU AND YOUR PATIENTS RotaTeq vaccine schedule RotaTeq combines its coverage with a flexible dosing schedule through three fully liquid, ready-to-use doses to help protect your pediatric patients.a aCan be completed as early as 14 weeks of age (doses given at 6, 10, and 14 weeks of age). Second and third doses should be given at 4-10 week intervals after previous dose. Third dose should not be given after 32 weeks of age. The safety and efficacy of RotaTeq have not been established in infants less than 6 weeks of age or greater than 32 weeks of age. Administration RotaTeq comes in a fully liquid, ready-to-use tube. In clinical trials, RotaTeq was routinely administered concomitantly with other licensed pediatric vaccines.b bIn clinical trials, RotaTeq was administered concomitantly with diphtheria and tetanus toxoids and acellular pertussis (DTaP), inactivated poliovirus vaccine (IPV), H. hepatitis B vaccine, and pneumococcal conjugate vaccine. RotaTeq is for oral use only. Not for injection. Looking to stock RotaTeq vaccines in your practice? Simply register or log in to your account to get started. CDC's ACIP RecommendationsFind out about the ACIP recommendations for rotavirus vaccination in pediatric patients. [6](#ref6rota) Reference Reference Indications and Usage for RotaTeq RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age. The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age. Selected Safety Information for RotaTeq RotaTeq\u00ae (Rotavirus Vaccine, Live, Oral, Pentavalent) should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine. Infants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered RotaTeq and later identified as having SCID. Infants with a history of intussusception should not receive RotaTeq. No safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised. In a post-marketing observational study in the US, cases of intussusception were observed in temporal association within 21 days following the first dose of RotaTeq, with a clustering of cases in the first 7 days. No safety or efficacy data are available for administration of RotaTeq to infants with a history of gastrointestinal disorders. Vaccine virus transmission from vaccine recipient to nonvaccinated contacts has been reported. Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts. In clinical trials, the most common adverse events included diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm. In post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq. RotaTeq may not protect all vaccine recipients against rotavirus. Before administering RotaTeq\u00ae (Rotavirus Vaccine, Live, Oral, Pentavalent), please read the accompanying [Prescribing Information](https://www.merck.com/product/usa/pi_circulars/r/rotateq/rotateq_pi.pdf). The [Patient Product Information](https://www.merck.com/product/usa/pi_circulars/r/rotateq/rotateq_ppi.pdf) also is available. Indications and Usage for RotaTeq\u00ae (Rotavirus Vaccine, Live, Oral, Pentavalent) Indications and Usage for RotaTeq RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age. The vaccination series consists of 3 ready-to-use liquid doses of RotaTeq administered orally starting at 6 to 12 weeks of age, with the subsequent doses administered at 4- to 10-week intervals. The third dose should not be given after 32 weeks of age. RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children RotaTeq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by Types G1, G2, G3, G4, and G9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. The first dose of RotaTeq should be administered between 6 and 12 weeks of age. Selected Safety Information for RotaTeq\u00ae (Rotavirus Vaccine, Live, Oral, Pentavalent) Selected Safety Information for RotaTeq RotaTeq\u00ae (Rotavirus Vaccine, Live, Oral, Pentavalent) should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine. Infants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged shedding of vaccine virus, have been reported in infants who were administered RotaTeq and later identified as having SCID. Infants with a history of intussusception should not receive RotaTeq. No safety or efficacy data are available from clinical trials regarding the administration of RotaTeq to infants who are potentially immunocompromised. In a post-marketing observational study in the US, cases of intussusception were observed in temporal association within 21 days following the first dose of RotaTeq, with a clustering of cases in the first 7 days. No safety or efficacy data are available for administration of RotaTeq to infants with a history of gastrointestinal disorders. Vaccine virus transmission from vaccine recipient to nonvaccinated contacts has been reported. Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts. In clinical trials, the most common adverse events included diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm. In post-marketing experience, intussusception (including death) and Kawasaki disease have been reported in infants who have received RotaTeq. RotaTeq may not protect all vaccine recipients against rotavirus. Before administering RotaTeq\u00ae (Rotavirus Vaccine, Live, Oral, Pentavalent), please read the accompanying [Prescribing Information](https://www.merck.com/product/usa/pi_circulars/r/rotateq/rotateq_pi.pdf). The [Patient Product Information](https://www.merck.com/product/usa/pi_circulars/r/rotateq/rotateq_ppi.pdf) also is available. RotaTeq should not be administered to infants with a demonstrated history of hypersensitivity RotaTeq should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine. Infants with Severe Combined Immunodeficiency Disease (SCID) should not receive RotaTeq. Post-marketing reports of gastroenteritis, including severe diarrhea and prolonged "}